Effects of 3 Years of Hormone Therapy, Raloxifene, and Alendronate on Mammographic Breast Density in Postmenopausal Korean Women.
- Author:
Myounghwan KIM
1
;
Hoon CHOI
Author Information
1. Department of Obstetrics and Gynecology, Inje University Sanggye Paik Hospital, Seoul, Korea. hchoi@paik.ac.kr
- Publication Type:Original Article
- Keywords:
Alendronate;
Hormone therapy;
Mammographic breast density;
Menopause;
Raloxifene
- MeSH:
Alendronate;
Breast;
Breast Neoplasms;
Estrogens;
Female;
Gynecology;
Humans;
Information Systems;
Menopause;
Obstetrics;
Raloxifene Hydrochloride;
Risk Factors
- From:The Journal of Korean Society of Menopause
2011;17(2):94-101
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: Breast density is an independent risk factor for the development of invasive breast cancer. We conducted this study to evaluate the effects of 3 years of hormone therapy, raloxifene, and alendronate on mammographic breast density in postmenopausal Korean women. METHODS: We studied 127 postmenopausal women who had visited the Department of Obstetrics and Gynecology of Inje University Sanggye Paik Hospital between January 2000 and June 2010. These patients were divided into the following 5 groups: alendronate (n = 26); raloxifene (n = 18); estrogen therapy (ET; n = 43); continuous estrogen-progesterone therapy (EPT; n = 20); and cyclic EPT (n = 20). The Breast Image Reporting and Data System (BI-RADS) composition grade 1, 2, and 3 years after treatment was compared with the BI-RADS composition grade at baseline. RESULTS: The BI-RADS grade decreased significantly in the raloxifene group at 1 year (P = 0.04). The BI-RADS grade increased significantly in the ET group at 3 years (P = 0.03), in the continuous EPT at 1, 2, and 3 years (P = 0.01, < 0.001, < 0.001, respectively), and in the cyclic EPT group at 2 and 3 years (P = 0.04 and 0.02, respectively). Although not statistically significant, a decrease in the BI-RADS grade occurred in the alendronate group at 1, 2, and 3 years (P = 0.08, 0.1, and 0.1, respectively). CONCLUSION: This study showed that there was significant decrease in mammographic breast density at 1 year in the raloxifene group and a decreasing trend in the alendronate group, whereas there was significant increase in the ET and EPT groups. To determine the effect of raloxifene and alendronate on breast density, larger prospective studies are needed.
